RecruitingPhase 1NCT06493084

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LAE102 Injection in Healthy and Overweight/Obese Subjects

Sponsor

Laekna Limited

Enrollment

160 participants

Start Date

Jun 25, 2024

Study Type

INTERVENTIONAL

Conditions

Overweight and Obese Volunteers

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LAE102 intravenous administration, a drug called LAE102 multiple subcutaneous administration, and others for people with overweight and obese volunteers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLAE102 intravenous administration

A single dose of LAE102 administered intravenously

DRUGplacebo intravenous administration

A single dose of placebo administered intravenously

DRUGLAE102 subcutaneous administration

Single dose of LAE102 administered subcutaneously

DRUGplacebo subcutaneous administration

single dose of placebo administered subcutaneously

DRUGLAE102 multiple subcutaneous administration

Multiple dose of LAE102 administered subcutaneously

DRUGPlacebo multiple subcutaneous administration

Multiple dose of placebo administered subcutaneously

Locations(1)

Fudan Zhongshan Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06493084

Related Trials

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

NCT067788501 location